JP2023501627A5 - - Google Patents

Info

Publication number
JP2023501627A5
JP2023501627A5 JP2022527859A JP2022527859A JP2023501627A5 JP 2023501627 A5 JP2023501627 A5 JP 2023501627A5 JP 2022527859 A JP2022527859 A JP 2022527859A JP 2022527859 A JP2022527859 A JP 2022527859A JP 2023501627 A5 JP2023501627 A5 JP 2023501627A5
Authority
JP
Japan
Prior art keywords
phenyl
fluoro
aml
week
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022527859A
Other languages
English (en)
Japanese (ja)
Other versions
JP7492002B2 (ja
JP2023501627A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2020/042410 external-priority patent/WO2021095840A1/en
Publication of JP2023501627A publication Critical patent/JP2023501627A/ja
Publication of JP2023501627A5 publication Critical patent/JP2023501627A5/ja
Application granted granted Critical
Publication of JP7492002B2 publication Critical patent/JP7492002B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022527859A 2019-11-13 2020-11-13 Lsd1阻害剤によりlsd1関連疾患及び障害を治療する方法 Active JP7492002B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962934923P 2019-11-13 2019-11-13
US62/934,923 2019-11-13
PCT/JP2020/042410 WO2021095840A1 (en) 2019-11-13 2020-11-13 METHODS OF TREATING LSD1-RELATED DISEASES and Disorders WITH LSD1 INHIBITORS

Publications (3)

Publication Number Publication Date
JP2023501627A JP2023501627A (ja) 2023-01-18
JP2023501627A5 true JP2023501627A5 (cg-RX-API-DMAC7.html) 2023-11-13
JP7492002B2 JP7492002B2 (ja) 2024-05-28

Family

ID=75912767

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022527859A Active JP7492002B2 (ja) 2019-11-13 2020-11-13 Lsd1阻害剤によりlsd1関連疾患及び障害を治療する方法
JP2022519478A Active JP7379680B2 (ja) 2019-11-13 2020-11-13 テルフェニル化合物の新規な塩

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022519478A Active JP7379680B2 (ja) 2019-11-13 2020-11-13 テルフェニル化合物の新規な塩

Country Status (18)

Country Link
US (2) US20220387384A1 (cg-RX-API-DMAC7.html)
EP (2) EP4058018A4 (cg-RX-API-DMAC7.html)
JP (2) JP7492002B2 (cg-RX-API-DMAC7.html)
KR (2) KR20220113390A (cg-RX-API-DMAC7.html)
CN (2) CN114728899B (cg-RX-API-DMAC7.html)
AU (2) AU2020382379B2 (cg-RX-API-DMAC7.html)
BR (2) BR112022009221A2 (cg-RX-API-DMAC7.html)
CA (1) CA3158442A1 (cg-RX-API-DMAC7.html)
DK (1) DK4058151T3 (cg-RX-API-DMAC7.html)
ES (1) ES3034158T3 (cg-RX-API-DMAC7.html)
FI (1) FI4058151T3 (cg-RX-API-DMAC7.html)
HU (1) HUE072206T2 (cg-RX-API-DMAC7.html)
MX (2) MX2022005811A (cg-RX-API-DMAC7.html)
PH (2) PH12022551137A1 (cg-RX-API-DMAC7.html)
PL (1) PL4058151T3 (cg-RX-API-DMAC7.html)
PT (1) PT4058151T (cg-RX-API-DMAC7.html)
TW (2) TWI874490B (cg-RX-API-DMAC7.html)
WO (2) WO2021095835A1 (cg-RX-API-DMAC7.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018276611B2 (en) 2017-05-31 2022-01-06 Taiho Pharmaceutical Co., Ltd. Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1
MX2022005811A (es) 2019-11-13 2022-06-08 Taiho Pharmaceutical Co Ltd Sal novedosa de compuesto de terfenilo.
JP2023548303A (ja) 2020-10-29 2023-11-16 大塚製薬株式会社 癌を処置する為の医薬組成物及びその使用方法
CA3231846A1 (en) 2021-04-08 2022-10-13 Tamara Maes Combinations of lsd1 inhibitors for treating myeloid cancers
CN117769540A (zh) * 2021-05-11 2024-03-26 亚士德制药公司 4-[5-[(3S)-3-氨基吡咯烷-l-羰基]-2-[2-氟-4-(2-羟基-2-乙基丙基)苯基]苯基]-2-氟-苯甲腈的盐的固体形式
TW202329934A (zh) * 2021-09-30 2023-08-01 日商大鵬藥品工業股份有限公司 使用聯苯化合物及免疫檢查點分子調節劑之用於癌症的組合療法
WO2023076302A1 (en) 2021-10-26 2023-05-04 Astex Pharmaceuticals, Inc. Process for preparing a benzoate salt of a 1-(3-aminopyrrolidine-1-carbonyl)-3,4-diphenylbenzene compound
US20250295660A1 (en) 2022-05-09 2025-09-25 Oryzon Genomics, S.A. Methods of treating nf1-mutant tumors using lsd1 inhibitors
US20250275969A1 (en) 2022-05-09 2025-09-04 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
US20260151399A1 (en) 2022-11-24 2026-06-04 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer
AU2024265282A1 (en) * 2023-05-02 2025-12-18 Taiho Pharmaceutical Co., Ltd. Response-based dosing for treating cancer with a hypomethylating agent and cedazuridine
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8801518D0 (sv) * 1988-04-22 1988-04-22 Astra Pharma Prod A novel process
US6225049B1 (en) 1992-06-17 2001-05-01 The United States Of America As Represented By The Department Of Health And Human Services Human insulinoma-associated cDNA
ATE484514T1 (de) 2001-12-13 2010-10-15 Natrogen Therapeutics Inc Derivate von isoindigo, indigo und indirubin und deren verwendung bei der behandlung von krebs
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
EP1792622A1 (en) 2005-11-11 2007-06-06 GPC Biotech AG Anti-proliferative combination therapy comprising a platinum-based chemotherapeutic agent and EGFR inhibitors or pyrimidine analogues
CA2732520A1 (en) 2008-08-05 2010-02-11 Merck Sharp & Dohme Corp. Therapeutic compounds
JP2012506238A (ja) 2008-10-20 2012-03-15 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイト インスリン様増殖因子−1受容体キナーゼ阻害剤に対する抗がん反応を予測する生物学的マーカー
US8367679B2 (en) 2008-12-09 2013-02-05 Merck Sharp & Dohme Corp. Biaryl carboxamides
WO2010120966A1 (en) 2009-04-17 2010-10-21 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
US8765820B2 (en) 2010-04-20 2014-07-01 Universita Degli Studi Di Roma “La Sapienza” Tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and/or LSD2
DK2598482T3 (en) 2010-07-29 2018-06-14 Oryzon Genomics Sa ARYLCYCLOPROPYLAMINE-BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE
EP2711704B1 (en) 2011-05-16 2017-06-28 Taiho Pharmaceutical Co., Ltd. Method for selecting chemotherapy for gastric cancer patient using combination drug of tegafur, gimeracil and oteracil potassium and egfr inhibitor
AU2012324803B9 (en) 2011-10-20 2017-08-24 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
BR112014028094B1 (pt) * 2012-05-09 2022-03-03 Cantex Pharmaceuticals, Inc Uso de um heparinoide interagindo com fator de plaqueta 4
WO2014151761A1 (en) 2013-03-15 2014-09-25 Ariad Pharmaceuticals, Inc. Novel choline kinase inhibitors
JP6521967B2 (ja) 2013-08-06 2019-05-29 イマーゴ バイオサイエンシーズ インコーポレイテッド 疾患の治療のためのkdm1a阻害剤
US9266907B2 (en) 2013-09-05 2016-02-23 King Abdullah University Of Science And Technology Tunable rare-earth fcu-metal-organic frameworks
CA3161836A1 (en) 2013-12-11 2015-06-18 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1
CN106061969B (zh) 2014-01-06 2019-10-29 阿尔戈么迪克斯有限公司 Trpa1调节剂
WO2015168466A1 (en) 2014-05-01 2015-11-05 Quanticel Pharmaceuticals, Inc. Inhibitors of lysine specific demethylase-1
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
AU2015309686B2 (en) 2014-08-25 2020-05-14 Epiaxis Therapeutics Pty Ltd Compositions for modulating cancer stem cells and uses therefor
ES2935114T3 (es) 2014-09-05 2023-03-01 Celgene Quanticel Res Inc Inhibidores de la desmetilasa 1 específica de lisina
AU2016252038B2 (en) 2015-04-20 2021-08-12 Effector Therapeutics, Inc. Inhibitors of immune checkpoint modulators for use in treating cancer and infections
WO2017013061A1 (en) 2015-07-17 2017-01-26 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
FI3381896T3 (fi) * 2015-11-27 2023-04-21 Taiho Pharmaceutical Co Ltd Bifenyyliyhdiste tai sen suola
WO2018136961A1 (en) 2017-01-23 2018-07-26 Syros Pharmaceuticals Inc. METHODS OF TREATING PATIENTS WITH A RETINOIC ACID RECEPTOR-α AGONIST AND AN ANTI-CD38 ANTIBODY
WO2018216795A1 (ja) * 2017-05-26 2018-11-29 大鵬薬品工業株式会社 新規なビフェニル化合物を用いた抗腫瘍効果増強剤
RU2765152C2 (ru) 2017-05-26 2022-01-26 Тайхо Фармасьютикал Ко., Лтд. Новое соединение бифенила или его соль
AU2018276611B2 (en) * 2017-05-31 2022-01-06 Taiho Pharmaceutical Co., Ltd. Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1
EP4201399A3 (en) 2017-06-30 2023-08-09 Celgene Corporation Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide
WO2019075327A1 (en) 2017-10-12 2019-04-18 Dana-Farber Cancer Institute, Inc. TREATMENT OF MERKEL CELL CARCINOMA
US11685782B2 (en) 2017-10-23 2023-06-27 Children's Medical Center Corporation Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy
AU2018377852B2 (en) 2017-11-29 2022-03-24 Epiaxis Therapeutics Pty Ltd Enhancing T-cell function and treating a T-cell dysfunctional disorder with a combination of an LSD inhibitor and a PD1 binding antagonist
US20210069356A1 (en) 2018-01-02 2021-03-11 Celgene Corporation Isotopologues of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
JP7730803B2 (ja) 2019-07-17 2025-08-28 サミット (オックスフォード) リミティド リジニラゾールの調製方法およびその結晶形態
MX2022005811A (es) 2019-11-13 2022-06-08 Taiho Pharmaceutical Co Ltd Sal novedosa de compuesto de terfenilo.
BR112022017637A2 (pt) 2020-03-06 2022-11-08 Celgene Quanticel Res Inc Métodos de tratamento do câncer de pulmão de células pequenas e/ou câncer de pulmão de células não pequenas

Similar Documents

Publication Publication Date Title
JP2023541430A5 (cg-RX-API-DMAC7.html)
JP2023541432A5 (cg-RX-API-DMAC7.html)
CN101636145B (zh) 长期24小时经肠给予左旋多巴/卡比多巴
AU2018357775B2 (en) New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)
PH12022551169A1 (en) METHODS OF TREATING LSD1-RELATED DISEASES and Disorders WITH LSD1 INHIBITORS
JP2021527092A5 (cg-RX-API-DMAC7.html)
JP2006504795A5 (cg-RX-API-DMAC7.html)
KR20060123482A (ko) 신장 기능을 개선하기 위한 트레프로스티닐의 용도
JP2014515373A5 (cg-RX-API-DMAC7.html)
BR112015010063B1 (pt) Uso de uma composição compreendendo colchicina, um sal de colchicina ou combinação desses
JP2014515408A5 (cg-RX-API-DMAC7.html)
JP2024531188A5 (cg-RX-API-DMAC7.html)
MY209220A (en) Dosing regimen for the treatment of pi3k related disorders
JP2018138596A5 (cg-RX-API-DMAC7.html)
JP2023537921A5 (cg-RX-API-DMAC7.html)
JP2024501919A5 (cg-RX-API-DMAC7.html)
JP2004521856A (ja) Cox−2選択的阻害剤およびトロンボキサン阻害剤を用いる併用療法ならびにそのための組成物
RU2007107915A (ru) Лекарственные средства для лечения хронического респираторного заболевания
WO2019178023A1 (en) Methods of Treating or Preventing Acute Respiratory Distress Syndrome
EP4087555A1 (en) Methods of using andrographolide, oridonin and isoliquiritigenin and derivatives thereof
JP2023553253A5 (cg-RX-API-DMAC7.html)
JP2016505050A5 (cg-RX-API-DMAC7.html)
JP2024531799A5 (cg-RX-API-DMAC7.html)
JP7208139B2 (ja) 双極性障害の予防、軽減又は治療のためのカルバメート化合物の使用
MX384760B (es) Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco y gabapentina para el tratamiento del dolor neuropático.